Search | Clinical Trials Finder

Conditions: Male Osteoporosis
Interventions: Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet, Calcium citrate tablet, Vitamin D3; Drug · Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years to 85 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions: Enzalutamide; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: Male only
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 9
States / cities: Anchorage, Alaska • Detroit, Michigan • New York, New York + 5 more

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more

Conditions: Obstructive Sleep Apnea
Interventions: Drug-induced sleep endoscopy (DISE), High-resolution manometry (HRM):; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 5 Years to 90 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Opioid Use Disorder, Opioid Use, Opioid Abuse, Opioid Misuse, Opioid Dependence
Interventions: buprenorphine/naloxone; Drug
Lead sponsor: Bicycle Health; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Interventions: Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil; Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 0 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cocaine Use Disorder
Interventions: Prize-Based Contingency Management, Treatment As Usual Outpatient Substance Use Treatment; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depression, End Stage Renal Disease
Interventions: Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Dallas, Texas • Seattle, Washington

Conditions: Air Pollution Exposure, Oxidative Stress, Airway Inflammation
Interventions: Antioxidant- and Nutrient-Rich Food-Based Nutrition Intervention; Other
Lead sponsor: Georgia Southern University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Savannah, Georgia

Conditions: Anxiety, Cardiovascular Disease
Interventions: Lexapro, Placebo, Supervised Aerobic Exercise; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 40 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dementia, Alzheimer Disease, Dementia, Vascular, Lewy Body Disease, Frontotemporal Lobar Degeneration, Memory Disorders
Interventions: Navigated Care; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 45 Years and older
Enrollment: 1,560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: San Francisco, California • Omaha, Nebraska

Conditions: Juvenile Delinquency Unspecified, Risk Behavior, Adolescent Behavior, Sexual Behavior, Drug Use
Interventions: Parent Ed. and Youth Skills Coaching, Services as Usual; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 13 Years to 18 Years · Female only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Unipolar Depression
Interventions: Bright light therapy, dim red light; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Medication Adherence, Kidney Transplantation
Interventions: Adherence Intervention, Healthy living education intervention; Behavioral · Other
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre; Other
Eligibility: 12 Years to 24 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more

Conditions: Pain, Postoperative
Interventions: Gabapentin 250mg/5mL NDC:59762-5025-01, Simple Syrup; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 10 Years to 19 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Peripheral Neuropathy
Interventions: Acupuncture; Other
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
Interventions: Single-Dose Antibiotic, Multi-Dose Antibiotic; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Depression, Palliative Care, Cancer, Mental Disorder
Interventions: Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI); Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Multiple Myeloma, Cancer
Interventions: Isatuximab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 5
States / cities: Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 2 more

Conditions: Chronic Sinusitis
Interventions: IV Acetaminophen, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 68 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
Interventions: Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna; Drug · Radiation · Procedure
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 15 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 11
States / cities: Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more

Conditions: Leukemia, Myeloid Leukemia, Monocytic Leukemia
Interventions: Venetoclax, Azacitidine, Mitoxantrone; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 53
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more

Conditions: Blood Pressure Monitoring, Hypertension (HTN), Pregnancy
Interventions: Enhanced Care Group, Remote Blood Pressure Monitoring alone; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbia, South Carolina

Search by objective public record fields.

Novel Combination Therapy for Osteoporosis in Men

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

Use of High-resolution Manometry to Detect Upper Airway Obstruction During Sleep

Novel Induction to Buprenorphine/Naloxone

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project

A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}

Savannah Environmental Nutrition Study (SENS): Nutrition Intervention to Reduce Air Pollution-Related Airway Inflammation and Oxidative Stress

Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

Care Ecosystem: Navigating Patients and Families Through Stages of Care

Safe, Healthy, Adolescent Relationships and Peers

Bright Light Therapy for Depressed Geriatric Inpatients

Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3

Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin

Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy

Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

Community Health Worker Coaching to Reduce Cardiovascular Risk Among Women After a Hypertensive Disorder of Pregnancy